Abstract:Inflammatory bowel diseases (IBD) are characterized by idiopathic chronic inflammation of the gastrointestinal tract, comprising the two major entities ulcerative colitis (UC) and Crohn's disease (CD). A series of studies have demonstrated that perturbations of the indigenous gut microbiota, persistent infections, environmental factors, and genetic variants contribute to dysregulated immune responses to microbiota, leading to the development of IBD.1, 2 The incidence and prevalence of IBD are increasing globally, particularly in developing countries. The precise etiologies and pathophysiology are unknown, and therefore medical therapy to cure these diseases is not yet available. Genome-wide association studies (GWAS) have identified > 240 genetic loci associated with human IBD. However, most IBD genetic associations have been derived using individuals from European (EUR) ancestries, with only a few studies of much smaller sample sizes in East Asian (EAS) ancestries, particularly the Chinese population.3, 4 Recently in Nat Genet, Liu et al. are the first to clarify the genetic architectures associated with human IBD using the largest samples from EAS ancestries including Chinese IBD patients.5 They identified 16 new genetic loci just across EAS ancestries. Variance explained for these IBD EAS loci across EUR and EAS was mainly by higher minor allele frequencies (MAFs) in EAS instead of similar effect sizes (average MAF 0.25 versus 0.17, two-sided paired t-test p = .015) (Figure 1), suggesting the importance of including global ancestries in genetic studies to ensure the relevance of the genetic findings.5 Furthermore, Liu et al. identified 81 new genetic loci associated with IBD across both EAS and EUR ancestries, thus increasing the number of IBD-associated genetic loci to 320 by comparing with 45 106 IBD cases and 353 562 healthy donors from East Asian countries (China, Korea and Japan), the International IBD Genetics Union (IIBDGC) and FinnGen.5 Variance explained by IBD-associated loci differs across EAS ancestries and EUR ancestries, which is, to a greater degree, driven by MAFs but less by the effect sizes (32% of IBD associations have different MAFs, and 22% have different odds ratios).5 Liu et al. have found that there is a comparable single nucleotide polymorphism-based heritability across EAS ancestries and EUR ancestries, indicating that the amount of genetic contribution to IBD is roughly the same across the two populations. Besides, Liu et al. found that the genetic effects of many IBD loci are consistent in both ancestries, with only a few loci as clear exceptions, for example, tumour necrosis factor super family 15 (TNFSF15), colony-stimulating factor 2 receptor subunit beta and interleukin 23 receptors. As the variance explained for IBD loci differs across ancestries, the ability to exploit genetic loci and predict an individual's disease risk of IBD also differs greatly. Liu et al. estimated this ability using polygenic risk score (PRS) and observed that PRS trained in the EUR population has a reduced accuracy in the EAS population. To some extent, the accuracy of predicting an individual's risk of CD or UC could be improved by jointly modeling EAS and EUR populations. Accordingly, the genetic diversity of the population plays a major role in GWAS for the equitable deployment of PRS in clinical settings.5 Susceptibility genes are significantly related to clinical manifestations, course of disease, and treatment response. Previous studies have shown that variants in nudix hydrolase 15 are associated with an increased risk of thiopurine-induced myelosuppression and that these variants have a great predictive power for thiopurine-induced myelosuppression.6 Precision and personalized medicine based on individual pharmacogenomic information enable the safe use of thiopurines by minimizing thiopurine-induced severe side effects (e.g. leukopenia and alopecia) in IBD patients. Moreover, the ATG16L1 genotype in CD patients largely affects the efficacy of corticosteroids, immunosuppressants, and biological agents.7 As a canonical autophagy-regulating protein, ATG16L1 has been found to be downregulated in different types of tissues in Chinese CD patients, suggesting that a conjoint analysis of protein and gene enables us to screen more variants in different populations.8 Previous reports have shown that the IL-23R genotype is an optimal predictor of an early response to anti-TNF-α monoclonal antibody (i.e., infliximab) in UC patients.9 Accumulating studies have tried to explore the association between the genetic characteristics and clinical phenotypes and outcome and found that nucleotide-binding oligomerization domain containing 2 (NOD2) gene polymorphisms are associated with age and complications of CD patients. Importantly, the most common genetic variant of ATG16L1 (rs2241880) is significantly associated with the development of CD perianal disease.7 Precision and personalized medicine is a hotspot of IBD study. The data converging multiple omics, data integration, computer networking models, and new clinical trials lay the foundation for precision medicine in the future.10 Liu et al. have highlighted the similarities and differences in the genetic architectures between EUR and EAS ancestries and pinpointed the clinical significances relevant to IBD genetic study for the first time.5 The latest research progress in genetic characteristics of IBD in Chinese and other EAS ancestries will help us to better understand the pathogenesis of IBD and provide precision medicine in these emerging regions with high incidences of disease, particularly in EAS countries (Figure 2). The authors declare no conflict of interest.

Tu1918 Intestinal Dendritic Cells Survey Circulatory Antigens Prior to Induction of Regulatory CD8a/ T Cells

Revisiting An Expression Dataset Of Discordant Inflammatory Bowel Disease Twin Pairs Using A Mutation Burden Test Reveals Cyp2c18 As A Novel Marker

Association of Polymorphisms in the IL‐10 Promoter Region with Crohn's Disease

Quantitative Proteomic Analysis Reveals the Deregulation of Nicotinamide Adenine Dinucleotide Metabolism and CD38 in Inflammatory Bowel Disease.

Intestinal Dendritic Cells Survey Circulatory Antigens Prior to Induction of Regulatory CD8α/β T Cells (106.2)

Su1766 Phenotype of Peripheral T Lymphocyte Did Not Correlate with Genotype at Rs7746082, a Confirmed Focal SNP on 6q21 for Crohn's Disease Susceptibility

Genetic Variation at Rs7746082 in a Confirmed CD Susceptibility Locus on 6q21 Correlates with Expression of PRDM1 but Not ATG5

Susceptibility Gene Profiling Elucidates the Pathogenesis of Inflammatory Bowel Disease and Provides Precision Medicine.

Nod2 Status And Human Ileal Gene Expression

Tu1917 Genetic Variation at IBD Genome Wide Association Study (GWAS) Associated Single-Nucleotide Polymorphisms Correlates with Expression of ERAP2 and CARD9 in Ileal Biopsies

Identification of Crucial Genes and Related-Transcription Factors in Ulcerative Colitis

Identification of Targets for Subsequent Treatment of Crohn's Disease Patients after Failure of Anti-TNF Therapy.

DOP81 Unaffected ileal transcriptomics in Crohn's disease is associated with the response to anti-TNF therapy

Antigen-driven expansion of public clonal T cell populations in inflammatory bowel diseases

DOP32 CD226+TIGITneg expression identifies pathogenic inflammatory CD4+ memory T cells in severe Crohn’s Disease patients, opening up opportunities for patient-tailored treatment strategies

Genetics of Inflammatory Bowel Disease in Asia: Systematic Review and Meta-Analysis

OCTN and CARD15 Gene Polymorphism in Chinese Patients with Inflammatory Bowel Disease

Single-Cell RNA Sequencing of Terminal Ileal Biopsies Identifies Signatures of Crohn's Disease Pathogenesis.

P015 CITE-seq analysis revealed immune cell diversity in colonic mesenteric lymph nodes from IBD patients

Single-Cell RNA-Sequencing Analysis of Colonic Lamina Propria Immune Cells Reveals the Key Immune Cell-Related Genes of Ulcerative Colitis

MUCOSAL EXPRESSION OF GENES PI3, ANXA1, AND VDR DESCRIMINATES CROHNS DISEASE FROM ULCERATIVE COLITIS IN INFLAMMATORY BOWEL DISEASE PATIENTS